Trial of Bendamustine And Rituximab for Patients With Previously Untreated Extranodal Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma
Multicentric, Non-Randomized Phase 2 Trial of Bendamustine And Rituximab for Patients With Previously Untreated Extranodal Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma
Sponsor: Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
This PHASE2 trial investigates MALT LYMPHOMA and is currently completed. Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea leads this study, which shows 6 recorded versions since 2009 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
6 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE2
▶ Show 1 earlier version
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE2
First recorded
May 2009
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Alcorcón, Spain , Badalona, Spain , Barcelona, Spain , L'Hospitalet de Llobregat, Spain , Madrid, Spain , Murcia, Spain , Oviedo, Spain , Palma de Mallorca, Spain , Pamplona, Spain , Salamanca, Spain and 5 more locations